Sign In
Buy ABCL
$5.80
-0.665 (-10.29%)
At Close: Jul 20, 2026
AbCellera Biologics Inc. (ABCL) Presents at TD Cowen 46th Annual Health Care Conference Transcript
03:15pm, Friday, 06'th Mar 2026
AbCellera Biologics Inc. (ABCL) Presents at TD Cowen 46th Annual Health Care Conference Transcript
AbCellera Biologics Pivots to Pipeline as ABCL635 Phase II Hot Flash Data Nears, Exec Says
02:06am, Friday, 06'th Mar 2026
AbCellera Biologics (NASDAQ: ABCL) is positioning itself as a more pipeline-driven biotechnology company after more than a decade of platform investment, according to comments from Senior Director of
What Sparked AbCellera Biologics To Soar Over 9% After Hours
03:51am, Wednesday, 25'th Feb 2026
AbCellera Biologics shares jumped 9.3% after hours to $3.52 following an 83% earnings beat in Q4 2025.
AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Tops Revenue Estimates
10:55pm, Tuesday, 24'th Feb 2026
AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.11 per share a year ago.
AbCellera Biologics Inc. (ABCL) Q4 2025 Earnings Call Transcript
07:27pm, Tuesday, 24'th Feb 2026
AbCellera Biologics Inc. (ABCL) Q4 2025 Earnings Call Transcript
AbCellera Reports Full Year 2025 Business Results
04:05pm, Tuesday, 24'th Feb 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Full Year 2025 Business Results.
AbCellera Biologics Inc. (NASDAQ:ABCL) Given Average Recommendation of “Hold” by Brokerages
02:08am, Wednesday, 18'th Feb 2026
AbCellera Biologics Inc. (NASDAQ: ABCL - Get Free Report) has received a consensus recommendation of "Hold" from the six ratings firms that are presently covering the stock, Marketbeat reports. One eq
AbCellera Biologics (ABCL) Projected to Post Earnings on Tuesday
04:52am, Tuesday, 17'th Feb 2026
AbCellera Biologics (NASDAQ: ABCL - Get Free Report) is expected to announce its Q4 2025 results after the market closes on Tuesday, February 24th. Analysts expect the company to announce earnings of
AbCellera to Present at Upcoming Investor Conferences in March and April 2026
04:05pm, Wednesday, 11'th Feb 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at Upcoming Investor Conferences in March and April 2026.
AbCellera to Report Full Year 2025 Financial Results on February 24, 2026
04:05pm, Thursday, 22'nd Jan 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Full Year 2025 Financial Results on February 24, 2026.
Citizens Financial Group Inc. RI Acquires Shares of 261,890 AbCellera Biologics Inc. $ABCL
04:06am, Thursday, 15'th Jan 2026
Citizens Financial Group Inc. RI bought a new position in AbCellera Biologics Inc. (NASDAQ: ABCL) during the third quarter, according to the company in its most recent 13F filing with the SEC. The fun
AbCellera Biologics Inc. (ABCL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
09:16pm, Wednesday, 14'th Jan 2026
AbCellera Biologics Inc. (ABCL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of VMS Due to Menopause
AbCellera Biologics Inc. (NASDAQ:ABCL) Given Average Recommendation of “Hold” by Analysts
03:18am, Tuesday, 30'th Dec 2025
Shares of AbCellera Biologics Inc. (NASDAQ: ABCL - Get Free Report) have been given a consensus rating of "Hold" by the seven brokerages that are presently covering the stock, Marketbeat reports. One
AbCellera and Bruker Reach Global Settlement of Patent Litigation
09:00am, Thursday, 18'th Dec 2025
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera and Bruker Reach Global Settlement of Patent Litigation.
